Livagen vs Cartalax: which one actually has evidence behind it

I get a version of this question every few weeks from people already deep into the Khavinson bioregulator peptides: they've heard of Livagen for liver support and Cartalax for joints, and they want to know which one is worth their money. Short answer: Cartalax has real, if preclinical, evidence behind it, while Livagen currently has none specific to the compound, so if you're choosing between the two on evidence alone, Cartalax is the stronger pick.

That's not a knock on Livagen as a concept. It's a description of what's actually been published.

What each peptide is actually claiming to do

Livagen is a four-amino-acid peptide (Lys-Glu-Asp-Ala) aimed at the liver. The claim is that it reopens silenced genes in liver cells by loosening up tightly packed chromatin, the DNA-protein complex that controls which genes a cell can access. That mechanism isn't invented out of nothing; it comes from broader Khavinson-family work on chromatin decondensation in hepatocytes, the liver cells that do most of the organ's metabolic and detox work. The catch: that study is a family-wide mechanism paper, not a Livagen-specific trial. Nobody has run Livagen itself through a study and measured what it does in a liver cell.

Cartalax is a three-amino-acid peptide (Ala-Glu-Asp) developed from cartilage tissue, and the name suggests joint-specific action. The published research doesn't actually test cartilage tissue directly; it tests fibroblasts, the cells that build and maintain connective tissue broadly (cartilage, tendons, skin, blood vessel walls), plus kidney cells. Same proposed mechanism family as Livagen: the peptide is thought to bind DNA and shift which genes an aging cell is reading, but here there's data to back it up.

The evidence gap, and it's a real gap

This is where the two compounds split hard. Human skin fibroblast work published in 2020 found that Cartalax activated SIRT-1 and SIRT-6, two proteins central to genome maintenance and longevity signaling, and stimulated collagen I synthesis in cells taken from actual human tissue rather than an animal model. A companion rat fibroblast study found Cartalax suppressed MMP-9, an enzyme that breaks down collagen and other structural proteins and ramps up with age. A separate kidney cell study found the same peptide reduced markers that push cells into senescence and increased SIRT-6 expression there too.

None of that is a human clinical trial. All three papers are in-vitro, meaning cells in a dish rather than a living organism, and none have been independently replicated outside the Khavinson research group. But it's three separate lab findings, two using human cells, all pointing the same direction. That's a real signal, even if it's an early one.

Livagen has nothing at that level. Its mechanism claim rests on a 2004 chromatin study that covers the Khavinson tetrapeptide family broadly and never tested Livagen by name. If you're the kind of reader who wants to see the actual data before you spend money on a peptide, Livagen currently gives you nothing to look at. Cartalax gives you three papers you can read yourself.

I tell people this a lot with the Khavinson compounds specifically: this whole family runs thinner on human data than BPC-157 or TB-500, and anyone expecting Western-style trial data here is going to be disappointed no matter which one they pick. The honest position is that both of these are speculative compounds, and Cartalax is just less speculative than Livagen.

Cost and side-effect load

Neither peptide has a documented history of serious adverse events, but neither has real pharmacovigilance data either, meaning nobody has systematically tracked side effects across a large population the way they would for an approved drug. What exists is scattered community reporting: occasional injection-site redness and mild transient headache with Livagen, injection-site redness and swelling with Cartalax. Low burden on paper, but "low burden on paper" for a peptide with zero dedicated safety studies is a different claim than "proven safe."

Cartalax carries one real red flag that Livagen doesn't: its proposed mechanism includes suppressing p53, a gene that normally puts the brakes on cell division when something goes wrong. That's part of why it may help aging cells behave more youthfully, but it's also exactly the kind of mechanism you don't want active in someone with cancer or a cancer history. If that describes you or someone you're advising, Cartalax is off the table regardless of how good the fibroblast data looks.

On cost, the two run similarly priced as Khavinson-family compounds, but Cartalax's dosing story is messier. The Khavinson-school protocol calls for 5 to 10 mcg per day, while the community consensus dose that's actually circulating is 2 mg per day, a 200 to 400 times difference with no dose-finding study to tell you which range is right. Livagen's dosing convention, borrowed generically from the wider bioregulator family, sits around 100 to 200 mcg per day for a 10 to 20 day course, repeated two to three times a year. That's the shape people are actually running it in, not a validated clinical protocol.

Standard disclaimer, and I mean it: the doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

Who each one actually suits

If you're chasing liver support specifically, Livagen is the only Khavinson option built for that tissue, but you should go in knowing you're extrapolating from family mechanism data, not compound-specific results. If you're chasing joint or connective-tissue maintenance and longevity framing, Cartalax has the better evidence trail, though it is not a substitute for BPC-157 or TB-500 if you're dealing with an actual acute injury; those two have a real clinical track record for repair work, and Cartalax is a maintenance layer you'd add on top once the acute problem is settled, not instead of it.

I see this mistake a lot with clients newer to peptides: they reach for the exotic Khavinson compound because it sounds specific to their problem, when a better-studied peptide aimed at the same broad goal would serve them better. If your actual goal is repairing a fresh injury, Cartalax is not that tool, and neither is Livagen.

Both of these also sit inside the part of the peptide market with the worst counterfeit problem. Khavinson-family peptides are the dominant gray-market counterfeit category out there, and thin published records for compounds like Livagen make mislabeling easy to get away with. A third-party certificate of analysis matters more here than almost anywhere else in this space, and it's worth reading one properly before you trust a vial.